Verici Dx (VRCI) Stock Overview

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.